In a nail-biter scenario, the NC General Assembly passed hemp legislation late this afternoon, one day before all of the state’s existing hemp laws are set to expire. We expect the bill to be signed by Governor Cooper shortly. Thank you to all of the NC hemp industry participants and hemp-friendly legislators who got this done.
In this keynote speech Rod addresses perils facing the hemp industry, including the threat posed by Big Marijuana, cannabis associations that purport to advocate for hemp while promoting corporate marijuana interests, and the current crisis for hemp in NC. Rod also discusses important federal law issues and practical recommendations for the hemp industry.
The Source Rule, which says that the source of a cannabinoid determines its legal status, is embedded into the legal fabric of the cannabis industry. In this article I respond to arguments claiming that the Source Rule is dead and show that, far from dead, it is now more relevant than ever.
Continue reading “The Source Rule is Alive and Well”…
The post The Source Rule is Alive and Well first appeared on Kight on Cannabis.
Virginia’s attempt to provide further clarity regarding hemp extract and hemp-derived products has instead resulted in additional and onerous regulations that challenge the vitality of an industry it once strongly supported.
Continue reading “Virginia Stomps Its Local Hemp Industry With New Law”…
The post Virginia Stomps Its Local Hemp Industry With New Law first appeared on Kight on Cannabis.
Since the DEA’s Seed Letter became public I have fielded a number of calls from clients about selling cannabis seeds. Everyone wants to know if it is possible to sell cannabis seeds and other low-THC cannabis materials, such as cannabis clones, and stay out of legal trouble. The answer is, “It depends”.
Continue reading “DEA Seed Letter – Triumph or Trap?”…
The post DEA Seed Letter – Triumph or Trap? first appeared on Kight on Cannabis.
Members of the legal team suing the DEA recently discussed the case, why it is critical to the hemp industry’s survival, and what a loss would mean for hemp companies across the nation. Watch the video here.
Continue reading “The Hemp Industry (Including D8) Needs Your Support to Defeat the DEA (Video)”…
The post The Hemp Industry (Including D8) Needs Your Support to Defeat the DEA (Video) first appeared on Kight on Cannabis.
Due to a combination of factors, the hemp and CBD industry as we now know it in North Carolina may be about to end very soon.
Continue reading “Is North Carolina’s Hemp and CBD Industry Coming to an Abrupt End?”…
The post Is North Carolina’s Hemp and CBD Industry Coming to an Abrupt End? first appeared on Kight on Cannabis.
Should delta-8 THC and other intoxicating hemp products be sold by convenience stores and other retailers? How can they be marketed and regulated to ensure that they are both safe and not easily obtained by minors? I discuss these and other issues in a recent video podcast on the CPG & CBD University Podcast.
Continue reading “Age Verification, Delta-8 THC, and Intoxicating Hemp Products (Video)”…
The post Age Verification, Delta-8 THC, and Intoxicating Hemp Products (Video) first appeared on Kight on Cannabis.
In June 2021 Kentucky state troopers raided two lawful hemp retail stores in Morehead, Kentucky regarding delta-8 THC and other novel cannabinoids. This article reports on a recent court injunction arising out of this raid.
Continue reading “New Legal Status of Delta-8 in the Bluegrass State”…
The post New Legal Status of Delta-8 in the Bluegrass State first appeared on Kight on Cannabis.
Watch an in-depth discussion about delta-8 THC and other cannabinoids, state regulation of hemp, and medical marijuana with Kight Law attorney Philip Snow and Joe Agostinelli of the CPG & CBD University Podcast.
Continue reading “Kight Law Attorney Philip Snow On the Future of Delta-8 THC and Other Cannabinoids (Video)”…
The post Kight Law Attorney Philip Snow On the Future of Delta-8 THC and Other Cannabinoids (Video) first appeared on Kight on Cannabis.
Marijuana impairs a driver’s reaction time, decision-making ability, capacity to accurately track objects, balance and equilibrium. Still, it is difficult to measure when a person is impaired. The intoxicating ingredient in cannabis, tetrahydrocannabinol (THC), is metabolized differently by individuals and remains in the body long after its psychoactive effects have ceased. Currently, there is no way to reliably measure whether a person who has ingested cannabis an hour earlier is impaired because THC concentration does not correlate well with subjective impairment.
The Pennsylvania Department of Health (DOH) reported that almost $100 million in medical marijuana sales occurred between February 15, 2018, and February 15, 2019, the first full year that medical cannabis was available to Pennsylvania patients. More than $40 million in sales occurred between growers and dispensaries. Pennsylvania does not tax sales to patients, but does tax transactions between growers and dispensaries at a rate of 5%. Thus, in the first year of licensed sales, the Commonwealth received approximately $2 million in tax revenue from medical cannabis.
The 2018 U.S. Farm Bill has opened the gates to industrial hemp farming. Hemp, a crop that has been banned in the United States since 1937, now may be legally grown. While the most popular product of hemp − oils containing cannabidiol (CBD) and other naturally occurring non-psychoactive cannabinoids − are still subject to conflicting federal and state regulations, the plant itself may be grown across the United States.
The Commonwealth of Pennsylvania wants medical researchers to study cannabis at Pennsylvania medical schools, eight of which have been certified as Academic Clinical Research Centers (ACRCs). ACRCs can contract with Clinical Registrants (CRs), entities that the Commonwealth will license to cultivate, package and dispense cannabis for medical research. An entire set of regulations, commonly referred to as “Chapter 20,” has been drafted, redrafted and amended to make medical research of cannabis a reality in the Commonwealth.
On December 18, 2018, the Pennsylvania Department of Health (DOH) issued 23 cannabis dispensary permits (Phase II licenses). Fifty entities have been awarded dispensary licenses, which is the total number allowed under Pennsylvania’s Medical Marijuana Act. Each licensee can operate up to three dispensaries, bringing the total number of possible dispensaries in Pennsylvania to 150.
As the legal status of cannabis evolves, state legislatures are confronted with a difficult moral issue – how should local and state governments treat persons convicted of offenses that are no longer illegal? Below is a discussion of some of the options.
But of course, the “hemp oil” or cannabidiol (CBD) remains illegal under state law. Even if the CBD is locally sourced and sold through a licensed dispensary, edibles are not legal in Pennsylvania. Edibles are presently restricted to underage patients New Jersey. Moreover, Pennsylvania’s Medical Marijuana Act (MMA) strictly prohibits advertising or packaging that appeal to children. Candy-shaped CBD probably runs afoul of the spirit of the MMA.
National legalization of cannabis is now a reality − in Canada and Uruguay. Further south, we are still waiting, our hopes stoked by committed legislators who assure us that changes are coming soon.
The Pennsylvania Commonwealth Court has decided a new case that may have a huge impact on cannabis licensing in the Mid-Atlantic region. The Commonwealth Court hears cases involving state and local government entities and state agencies in Pennsylvania and has heard a number of challenges regarding the administration of the 2016 Medical Marijuana Act (MMA).
On September 21, 2018, the Commonwealth of Pennsylvania certified eight medical schools as Academic Clinical Research Centers (ACRCs). The following schools are now certified by the Commonwealth of Pennsylvania to contract with Clinical Registrants (CRs) to conduct medical research: